OrderlyMeds and Veo Health Partner to Pair GLP-1 Therapies with Biomarker Testing
核心洞察
OrderlyMeds (搜索) and Veo Health (搜索) announced a strategic partnership pairing GLP-1 (搜索), peptide, and longevity therapies with advanced biomarker testing and body composition analysis.
OrderlyMeds (搜索) customers gain access to two Veo Health (搜索) membership tiers: Veo Core (60+ biomarkers, AI insights) and Veo Pro (80+ biomarkers, consultations, personalized action plan).
Veo Health (搜索) members receive discounted access to OrderlyMeds (搜索)' therapeutic platform and clinical network, connecting the full arc of health optimization.
OrderlyMeds (搜索) and Veo Health (搜索) have announced a strategic partnership that looks past the scale, pairing OrderlyMeds' GLP-1 (搜索), peptide and longevity therapies with Veo Health's advanced biomarker testing and body composition analysis. The collaboration, announced September 9, 2026, aims to let customers monitor health improvements and assess specific changes to their health during a weight-loss journey.
Through the partnership, OrderlyMeds (搜索) customers gain access to two new Veo Health (搜索) membership tiers built for the GLP-1 (搜索) journey: Veo Core, which includes 60+ biomarkers and AI-powered insights, and Veo Pro, which includes 80+ biomarkers, physician and health-advisor consultations, and a personalized health action plan. Veo Health members, in turn, receive discounted access to OrderlyMeds' therapeutic platform and clinical network.
"At Orderly, we believe the best treatment is prevention. By pairing our accessible therapeutic programs with Veo's health monitoring and coaching platform, we're giving people a complete toolkit — not just to manage their health, but to get ahead of it," said Chris Spears, CEO, Orderly Wellness Corporation (搜索). "Partnering with Veo gives our customers a much broader view of their health — and the tools and expertise to act on what they learn."
The partnership connects what the companies describe as the full arc of health optimization — measure, understand, treat, monitor and optimize — pairing Veo Health (搜索)'s national lab and mobile phlebotomy network, DEXA scans, wearable-device integrations and concierge clinical experts with OrderlyMeds (搜索)' prescribing, coaching and clinical infrastructure.
"The goal isn't simply to help someone lose weight," said David Harvey, CEO, Veo Health (搜索). "It's to use that journey as a catalyst for better health and longevity."
As part of Orderly Wellness, OrderlyMeds (搜索) is a telemedicine platform connecting customers with licensed physicians across all 50 states to access prescription GLP-1 (搜索) medications, including compounded and brand-name treatments. The company reports that more than 125,000 customers have used OrderlyMeds to improve their health, collectively shedding over 1 million pounds, with individual results varying.
Veo Health (搜索), based in Atlanta, is a physician-led preventive health platform that helps individuals identify health risks earlier and act on them through advanced biomarker screenings and imaging, along with guidance from physicians, functional nutritionists and health advisors.
The companies note that compounded GLP-1 (搜索) medications are not FDA-approved and are not generic versions of, or substitutes for, FDA-approved drugs. They are prescribed only based on an individualized medical determination by a licensed healthcare provider.